Current guidelines do not explicitly recommend statin use in heart failure (HF). Relatively low numbers
of atherothrombotic events among HF patients, in the context of their elevated competing risks for
non-atherothrombotic causes of death, may have prevented previous analyses of clinical trials from detecting a
benefit for statins. We pooled data from two landmark trials of HF patients not on statin therapy randomized to
rosuvastatin 10 mg daily vs. placebo, CORONA and GISSI-HF, in order to improve our power to detect statistically
significant differences in atherothrombotic events. We also accounted for competing risks from other causes of
death.